SCHEMBL4865325

SCHEMBL4865325

CCSc1nc(NCCO)c2ccccc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.57
HTT P42858 3/20 0.54
POLB P06746 2/20 0.54
TAAR1 Q96RJ0 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PGK1 P00558 1/20 0.53
KDM4E B2RXH2 3/20 0.51
RAD52 P43351 4/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 3/20 0.51
GAA P10253 2/20 0.51
MITF O75030 1/20 0.51
TTR P02766 1/20 0.51
GLA P06280 1/20 0.51
RAB9A P51151 1/20 0.51
GBA1 P04062 1/20 0.51
MAPT P10636 3/20 0.50
HPGD P15428 1/20 0.50
SLC2A1 P11166 1/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866812 0.87 MAPT (0.48) MAPK1HTTPOLBTAAR1SMN1; SMN2
SCHEMBL4867045 0.86 ACP1 (0.63) MAPK1POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4864553 0.85 LMNA (0.65) MAPK1HTTKDM4ELMNAMAPT
SCHEMBL4867969 0.84 MAPT (0.59) MAPK1KDM4EALDH1A1LMNAMAPT
SCHEMBL4868696 0.83 LMNA (0.57) LMNAGBA1MAPTAPPPDE5A
SCHEMBL4863793 0.82 APP (0.62) POLBSMN1; SMN2KDM4ERAD52ALDH1A1
SCHEMBL4866041 0.82 LMNA (0.56) MAPK1KDM4ELMNAGBA1MAPT
SCHEMBL4866137 0.81 ACP1 (0.60) MAPK1POLBKDM4EALDH1A1LMNA
SCHEMBL4909339 0.80 TOP2A (0.57) MAPK1POLBALDH1A1LMNAMAPT
SCHEMBL4864291 0.80 KDM4E (0.53) MAPK1POLBSMN1; SMN2KDM4ERAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPK1 513/4885HTT 2611/4885POLB 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.